InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from the Phase 3 study of vilobelimab ...
With inflation back in the economic picture, simply getting a dependable income stream may not be the best strategy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results